



<b>Information Disclosure Statement By Applicant</b>  Page 1 of 2	Docket: SEQ-2	PATENT
	Title: Cancer Immunotherapy Using Autologous Tumor Cells Combined with Allogeneic Cytokine-Secreting Cells	U.S.S.N. 09/162,648
	Inventor: J.C. Hiserodt	Art Unit: 1633
	Filing Date: November 29, 1998	Examiner: Carrie Stroup, Ph.D

### U.S. Patent Documents

Examiner Initial	Ref	Patent	Filing Date	Issue Date	Class/ Subclass	Inventors	Title

### Foreign Patents and Published Foreign Patent Applications

Examiner Initial	Ref	Serial No.	Publication Date	Jurisdiction	Title	Translation	
						Yes	No
MS	A	WO 99/18981	Apr 22/99	PCT	<del>Implants Comprising Combinations of Allogeneic Cells for Use in Cancer Treatment (claiming priority to USCN 99/091,799, 9/29/98)</del>	✓	
MS	B	WO 99/19462	Apr 22/99	PCT	<del>Enhanced Immunogenic Cell Populations Prepared Using T2 Receptor Antagonists</del>	✓	

### Other Documents

Examiner Initial	Ref.	Description of Item
MS	C	Declaration by Tetsuya Gatanaga Pursuant to 37 CFR § 1.56 Regarding Clinical Trial Conducted under IND-6288 (5 pages)
MS	D	Appendix A to Declaration by Tetsuya Gatanaga: Curriculum Vitae (15 pages)
MS	E	Appendix B to Declaration by Tetsuya Gatanaga: Data from Clinical Trial, Protocol AIT-PAN-20 (12 pages)
	F	<del>Stornio et al., Cancer 15:1261-8, 1999. "An investigational new drug treatment program with gemcitabine: results for over 3000 patients with pancreatic cancer." (Complete article)</del>
MS	G	Hidalgo et al., J. Clin. Oncol. 17:585-92, 1999. "Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer" (Abstract only)
MS	H	Dugan et al., Pancreas 17:325-33, 1998. "Current concepts in pancreatic cancer: Symposium summary" (Abstract only)
MS	I	Stephens, Oncol. Nurs. Forum 25:87-93, 1998. "Gemcitabine: A new approach to treating pancreatic cancer" (Abstract only)
MS	J	Carmichael, Digestion 58:503-7, 1997. "Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine" (Abstract only)
MS	K	Burris et al., Eur. J. Cancer 33:S18-22, 1997. "Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil" (Abstract only)
MS	L	Rotherberg et al., Ann. Oncol. 7:347-53, 1996. "A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer" (Abstract only)
MS	M	Carmichael et al., Br. J. Cancer 73:101-5, 1996. "Phase II study of gemcitabine in patients with advanced pancreatic cancer" (Abstract only)



<b>Information Disclosure Statement By Applicant</b>  Page 2 of 2	Doc. No. SEQ-2	PATENT
	Title: Cancer Immunotherapy Using Autologous Tumor Cells Combined with Allogeneic Cytokine-Secreting Cells  Inventor: J.C. Hiserodt  Filing Date: November 29, 1998	U.S.S.N. 09/162,648  Art Unit: 1633  Examiner: Carrie Stroup, Ph.D

#### Other Documents

Examiner Initial	Ref	Description of Item
MS	N	Casper et al., Invest. New Drugs 12:29-34, 1994. "Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas" (Abstract only)
MS	O	Burris et al., J. Clin. Oncol. 15:2403-13, 1997. "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial" (Abstract only)
MS	P	Michael et al., Oncology (Huntingt) 11:1615-22, 1625-7, 1997. "Clinical experience with gemcitabine in pancreatic carcinoma" (Abstract only)

Examiner <i>Carrie MS</i>	Date Considered <i>9/12/00</i>
------------------------------	-----------------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.